Zinbryta superior to Avonex in Phase III DECIDE trial for Multiple Sclerosis- Biogen + AbbVie

Biogen Idec and AbbVie announced the full results from the Phase III DECIDE clinical trial, which show Zinbryta (daclizumab high-yield process), dosed subcutaneously once a month, demonstrated a statistically significant improvement in reducing disease activity in people with relapsing-remitting Multiple Sclerosis (RRMS) compared to Avonex (interferon beta-1a). These results are being presented at the Sixth Triennial Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-ECTRIMS) in Boston.

Patients on Zinbryta demonstrated a statistically significant 45 percent reduction in annualized relapse rate (ARR) compared to patients treated with Avonex. (p<0.0001). zinbryta demonstrated superiority in reducing the number of new or newly enlarging t2-hyperintense lesions at week 96, with a 54 percent reduction relative to avonex(p><0.0001).the risk of three-month confirmed disability progression, as measured by the expanded disability status scale (edss), was reduced by 16 percent in patients treated with zinbryta compared to those on avonex (p="0.16)." this was not statistically significant. seventy-three percent of zinbryta patients were relapse-free compared to 59 percent of avonex patients (nominal p><0.0001) at week 96.>

Biogen Idec and AbbVie plan to file marketing applications for Zinbryta with regulatory authorities during the first half of 2015.